Genome-wide Analysis Identifies Novel Loci Associated with Ovarian Cancer Outcomes: Findings from the Ovarian Cancer Association Consortium
暂无分享,去创建一个
A. Whittemore | L. Kiemeney | M. Pike | M. Beckmann | P. Fasching | R. Vierkant | T. Sellers | A. Hein | J. Chang-Claude | B. Fridley | E. Goode | Y. Chiew | A. deFazio | B. Karlan | A. Berchuck | E. Iversen | D. Lambrechts | D. Stram | D. Levine | L. Wilkens | P. Hillemanns | A. Ziogas | H. Anton-Culver | R. Glasspool | U. Menon | A. Gentry-Maharaj | D. Eccles | G. Chenevix-Trench | L. Brinton | J. Lissowska | J. Beesley | S. Orsulic | J. Cunningham | M. Goodman | S. Kjaer | A. Ekici | A. Jakubowska | J. Lubiński | A. Wu | P. Pharoah | J. Tyrer | S. Gayther | D. Cramer | N. Wentzensen | I. Vergote | R. Sutphen | R. Ness | I. Campbell | I. Orlow | J. Doherty | J. Schildkraut | K. Moysich | F. Modugno | L. Massuger | E. Bandera | C. Pearce | F. Heitz | P. Harter | A. du Bois | M. Carney | J. Lester | C. Cybulski | V. McGuire | J. Rothstein | W. Sieh | C. Walsh | M. Rossing | C. Kennedy | S. Winham | Honglin Song | P. Webb | A. Jensen | J. Gronwald | N. Siddiqui | E. Høgdall | C. Høgdall | S. Ramus | V. Rhenius | S. Kar | J. Paul | I. Rzepecka | A. Dansonka-Mieszkowska | J. Kupryjańczyk | Yi Lu | P. Thompson | Yukie T. Bean | K. Carty | S. Lambrechts | L. Lundvall | I. Schwaab | B. Śpiewankiewicz | K. Terry | S. Johnatty | M. Larson | E. Van Nieuwenhuysen | I. McNeish | Madalene Earp | B. Gao | S. Macgregor | Jacobus Pisterer | T. Pejovic | Zachary C. Fogarty
[1] A. Whittemore,et al. Germline Mutation in BRCA1 or BRCA2 and Ten-Year Survival for Women Diagnosed with Epithelial Ovarian Cancer , 2014, Clinical Cancer Research.
[2] Francisco Azuaje,et al. Databases for lncRNAs: a comparative evaluation of emerging tools , 2014, RNA.
[3] Shan Jiang,et al. Yap1 Activation Enables Bypass of Oncogenic Kras Addiction in Pancreatic Cancer , 2014, Cell.
[4] B. Davidson,et al. APOA1 mRNA expression in ovarian serous carcinoma effusions is a marker of longer survival. , 2014, American journal of clinical pathology.
[5] Joshy George,et al. ABCA transporter gene expression and poor outcome in epithelial ovarian cancer. , 2014, Journal of the National Cancer Institute.
[6] Joseph Rosenbluh,et al. KRAS and YAP1 Converge to Regulate EMT and Tumor Survival , 2014, Cell.
[7] J. Bartek,et al. PARK2 orchestrates cyclins to avoid cancer , 2014, Nature Genetics.
[8] Leina Ma,et al. Overexpression of the transcription factor MEF2D in hepatocellular carcinoma sustains malignant character by suppressing G2-M transition genes. , 2014, Cancer research.
[9] W. Jiang,et al. The Plexin-B family and its role in cancer progression. , 2014, Histology and histopathology.
[10] G. Mills,et al. Activation of YAP1 is associated with poor prognosis and response to taxanes in ovarian cancer. , 2014, Anticancer research.
[11] M. Beckmann,et al. ABCB1 (MDR1) polymorphisms and ovarian cancer progression and survival: a comprehensive analysis from the Ovarian Cancer Association Consortium and The Cancer Genome Atlas. , 2013, Gynecologic oncology.
[12] C. Baines,et al. Physiological and pathological roles of mitochondrial SLC25 carriers. , 2013, The Biochemical journal.
[13] Brooke L. Fridley,et al. GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer , 2013, Nature Genetics.
[14] J. Mattick,et al. Structure and function of long noncoding RNAs in epigenetic regulation , 2013, Nature Structural &Molecular Biology.
[15] Michael Rehman,et al. Semaphorins in cancer: biological mechanisms and therapeutic approaches. , 2013, Seminars in cell & developmental biology.
[16] J. Marchini,et al. Fast and accurate genotype imputation in genome-wide association studies through pre-phasing , 2012, Nature Genetics.
[17] J. George,et al. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] Inge Jonassen,et al. Linkage-disequilibrium-based binning affects the interpretation of GWASs. , 2012, American journal of human genetics.
[19] Z. Szallasi,et al. Implementing an online tool for genome-wide validation of survival-associated biomarkers in ovarian-cancer using microarray data from 1287 patients. , 2012, Endocrine-related cancer.
[20] H. Mackay,et al. Genetic polymorphisms as predictive and prognostic biomarkers in gynecological cancers: a systematic review. , 2012, Gynecologic oncology.
[21] D. Spandidos,et al. 'Genetic profiling' and ovarian cancer therapy (review). , 2011, Molecular medicine reports.
[22] Brooke L. Fridley,et al. Platinum Sensitivity–Related Germline Polymorphism Discovered via a Cell-Based Approach and Analysis of Its Association with Outcome in Ovarian Cancer Patients , 2011, Clinical Cancer Research.
[23] Jing Li,et al. Pharmacogenomics of drug metabolizing enzymes and transporters: implications for cancer therapy , 2011, Pharmacogenomics and personalized medicine.
[24] C. Mathers,et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 , 2010, International journal of cancer.
[25] Feng Gao,et al. Apolipoprotein A-I (apoA-I) and apoA-I mimetic peptides inhibit tumor development in a mouse model of ovarian cancer , 2010, Proceedings of the National Academy of Sciences.
[26] S. Hilsenbeck,et al. Hippo pathway effector Yap is an ovarian cancer oncogene. , 2010, Cancer research.
[27] A. Whittemore,et al. Common variants at 19p13 are associated with susceptibility to ovarian cancer , 2010, Nature Genetics.
[28] Ayellet V. Segrè,et al. Common Inherited Variation in Mitochondrial Genes Is Not Enriched for Associations with Type 2 Diabetes or Related Glycemic Traits , 2010, PLoS genetics.
[29] Yun Li,et al. METAL: fast and efficient meta-analysis of genomewide association scans , 2010, Bioinform..
[30] K. Irvine,et al. Yorkie: the final destination of Hippo signaling. , 2010, Trends in cell biology.
[31] Howard Y. Chang,et al. Long noncoding RNA HOTAIR reprograms chromatin state to promote cancer metastasis , 2010, Nature.
[32] Claudia Marchetti,et al. First-line treatment of advanced ovarian cancer: current research and perspectives , 2010, Expert review of anticancer therapy.
[33] K. Byth,et al. ABCB1 (MDR 1) Polymorphisms and Progression-Free Survival among Women with Ovarian Cancer following Paclitaxel/Carboplatin Chemotherapy , 2008, Clinical Cancer Research.
[34] E. Halperin,et al. Estimating Local Ancestry in Admixed Populations , 2022 .
[35] Shiwei Duan,et al. Identification of genetic variants contributing to cisplatin-induced cytotoxicity by use of a genomewide approach. , 2007, American journal of human genetics.
[36] M. Pirmohamed,et al. ABCB1 genotype and PGP expression, function and therapeutic drug response: a critical review and recommendations for future research , 2007, The Pharmacogenomics Journal.
[37] I. Dunham,et al. The DNA sequence and biological annotation of human chromosome 1 , 2006, Nature.
[38] D. Reich,et al. Principal components analysis corrects for stratification in genome-wide association studies , 2006, Nature Genetics.
[39] P. Söderkvist,et al. mdr-1 Single Nucleotide Polymorphisms in Ovarian Cancer Tissue: G2677T/A Correlates with Response to Paclitaxel Chemotherapy , 2006, Clinical Cancer Research.
[40] E. Olson,et al. A WW domain protein TAZ is a critical coactivator for TBX5, a transcription factor implicated in Holt-Oram syndrome. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[41] Pablo Tamayo,et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[42] A. Mes-Masson,et al. Chemosensitivity and radiosensitivity profiles of four new human epithelial ovarian cancer cell lines exhibiting genetic alterations in BRCA2, TGFβ-RII, KRAS2, TP53 and/or CDNK2A , 2004, Cancer Chemotherapy and Pharmacology.
[43] Robert S Mannel,et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[44] R. Ozols. Ovarian Cancer: American Cancer Society Atlas of Clinical Oncology , 2003 .
[45] Howard L McLeod,et al. Pharmacogenomics--drug disposition, drug targets, and side effects. , 2003, The New England journal of medicine.
[46] Mary V. Relling,et al. Pharmacogenetics and cancer therapy , 2001, Nature Reviews Cancer.
[47] B K Tang,et al. Hypothesis: comparisons of inter- and intra-individual variations can substitute for twin studies in drug research. , 1998, Pharmacogenetics.
[48] E. Venkatraman,et al. BRCA1 up-regulation is associated with repair-mediated resistance to cis-diamminedichloroplatinum(II). , 1998, Cancer research.
[49] S. Orsulic,et al. Ovarian Cancer , 1993, British Journal of Cancer.
[50] C. Mathers,et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer , 2013 .
[51] M. Weller,et al. Chromosomal imbalances associated with response to chemotherapy and cytotoxic cytokines in human malignant glioma cell lines , 2001, International journal of cancer.
[52] E. Vesell,et al. Pharmacogenetic perspectives gained from twin and family studies. , 1989, Pharmacology & therapeutics.